Health Trials

Anaplastic Lymphoma Kinase Gene Mutation

1

Review clinical trials related to Anaplastic Lymphoma Kinase Gene Mutation. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). The RCT will compare the use of Therapeutic Drug Monitoring (TDM) and dose increases if alectinib 35 ng/Ml (arm A) with standard of care (arm B).

Participants needed: 196
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: University Medical Center GroningenUpdated: May 13, 2024Locations: 8
Eligibility criteria

Patients with locally advanced or metastatic NSCLC (stage IIIB to stage IV by AJ... [+9]

Any significant concomitant disease determined by the investigator to be potenti... [+3]

Read more